List of Tables
Table 1. Antibody Drug Conjugate Therapeutics Market Trends
Table 2. Antibody Drug Conjugate Therapeutics Market Drivers & Opportunity
Table 3. Antibody Drug Conjugate Therapeutics Market Challenges
Table 4. Antibody Drug Conjugate Therapeutics Market Restraints
Table 5. Global Antibody Drug Conjugate Therapeutics Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Antibody Drug Conjugate Therapeutics Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Antibody Drug Conjugate Therapeutics Product Type
Table 9. Key Companies Time to Begin Mass Production of Antibody Drug Conjugate Therapeutics
Table 10. Global Antibody Drug Conjugate Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody Drug Conjugate Therapeutics as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Antibody Drug Conjugate Therapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Antibody Drug Conjugate Therapeutics Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Antibody Drug Conjugate Therapeutics Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Antibody Drug Conjugate Therapeutics Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Antibody Drug Conjugate Therapeutics Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Antibody Drug Conjugate Therapeutics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Antibody Drug Conjugate Therapeutics Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Antibody Drug Conjugate Therapeutics Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Antibody Drug Conjugate Therapeutics Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Antibody Drug Conjugate Therapeutics Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Antibody Drug Conjugate Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Antibody Drug Conjugate Therapeutics Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Antibody Drug Conjugate Therapeutics Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Antibody Drug Conjugate Therapeutics Sales Value by Region (2019-2024) & (%)
Table 27. Global Antibody Drug Conjugate Therapeutics Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Antibody Drug Conjugate Therapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Antibody Drug Conjugate Therapeutics Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Antibody Drug Conjugate Therapeutics Sales Value, (2025-2030) & (US$ Million)
Table 31. Bayer AG Basic Information List
Table 32. Bayer AG Description and Business Overview
Table 33. Bayer AG Antibody Drug Conjugate Therapeutics Products, Services and Solutions
Table 34. Revenue (US$ Million) in Antibody Drug Conjugate Therapeutics Business of Bayer AG (2019-2024)
Table 35. Bayer AG Recent Developments
Table 36. Pfizer Basic Information List
Table 37. Pfizer Description and Business Overview
Table 38. Pfizer Antibody Drug Conjugate Therapeutics Products, Services and Solutions
Table 39. Revenue (US$ Million) in Antibody Drug Conjugate Therapeutics Business of Pfizer (2019-2024)
Table 40. Pfizer Recent Developments
Table 41. Hoffman-Le Roche Basic Information List
Table 42. Hoffman-Le Roche Description and Business Overview
Table 43. Hoffman-Le Roche Antibody Drug Conjugate Therapeutics Products, Services and Solutions
Table 44. Revenue (US$ Million) in Antibody Drug Conjugate Therapeutics Business of Hoffman-Le Roche (2019-2024)
Table 45. Hoffman-Le Roche Recent Developments
Table 46. Seattle Genetics Basic Information List
Table 47. Seattle Genetics Description and Business Overview
Table 48. Seattle Genetics Antibody Drug Conjugate Therapeutics Products, Services and Solutions
Table 49. Revenue (US$ Million) in Antibody Drug Conjugate Therapeutics Business of Seattle Genetics (2019-2024)
Table 50. Seattle Genetics Recent Developments
Table 51. ImmunoGen Basic Information List
Table 52. ImmunoGen Description and Business Overview
Table 53. ImmunoGen Antibody Drug Conjugate Therapeutics Products, Services and Solutions
Table 54. Revenue (US$ Million) in Antibody Drug Conjugate Therapeutics Business of ImmunoGen (2019-2024)
Table 55. ImmunoGen Recent Developments
Table 56. Genentech Basic Information List
Table 57. Genentech Description and Business Overview
Table 58. Genentech Antibody Drug Conjugate Therapeutics Products, Services and Solutions
Table 59. Revenue (US$ Million) in Antibody Drug Conjugate Therapeutics Business of Genentech (2019-2024)
Table 60. Genentech Recent Developments
Table 61. Synthon Holding Basic Information List
Table 62. Synthon Holding Description and Business Overview
Table 63. Synthon Holding Antibody Drug Conjugate Therapeutics Products, Services and Solutions
Table 64. Revenue (US$ Million) in Antibody Drug Conjugate Therapeutics Business of Synthon Holding (2019-2024)
Table 65. Synthon Holding Recent Developments
Table 66. Sanofi Basic Information List
Table 67. Sanofi Description and Business Overview
Table 68. Sanofi Antibody Drug Conjugate Therapeutics Products, Services and Solutions
Table 69. Revenue (US$ Million) in Antibody Drug Conjugate Therapeutics Business of Sanofi (2019-2024)
Table 70. Sanofi Recent Developments
Table 71. Genmab Basic Information List
Table 72. Genmab Description and Business Overview
Table 73. Genmab Antibody Drug Conjugate Therapeutics Products, Services and Solutions
Table 74. Revenue (US$ Million) in Antibody Drug Conjugate Therapeutics Business of Genmab (2019-2024)
Table 75. Genmab Recent Developments
Table 76. Amgen Basic Information List
Table 77. Amgen Description and Business Overview
Table 78. Amgen Antibody Drug Conjugate Therapeutics Products, Services and Solutions
Table 79. Revenue (US$ Million) in Antibody Drug Conjugate Therapeutics Business of Amgen (2019-2024)
Table 80. Amgen Recent Developments
Table 81. Novartis Basic Information List
Table 82. Novartis Description and Business Overview
Table 83. Novartis Antibody Drug Conjugate Therapeutics Products, Services and Solutions
Table 84. Revenue (US$ Million) in Antibody Drug Conjugate Therapeutics Business of Novartis (2019-2024)
Table 85. Novartis Recent Developments
Table 86. Eli Lilly Basic Information List
Table 87. Eli Lilly Description and Business Overview
Table 88. Eli Lilly Antibody Drug Conjugate Therapeutics Products, Services and Solutions
Table 89. Revenue (US$ Million) in Antibody Drug Conjugate Therapeutics Business of Eli Lilly (2019-2024)
Table 90. Eli Lilly Recent Developments
Table 91. Key Raw Materials Lists
Table 92. Raw Materials Key Suppliers Lists
Table 93. Antibody Drug Conjugate Therapeutics Downstream Customers
Table 94. Antibody Drug Conjugate Therapeutics Distributors List
Table 95. Research Programs/Design for This Report
Table 96. Key Data Information from Secondary Sources
Table 97. Key Data Information from Primary Sources
Table 98. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Antibody Drug Conjugate Therapeutics Product Picture
Figure 2. Global Antibody Drug Conjugate Therapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Antibody Drug Conjugate Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 4. Antibody Drug Conjugate Therapeutics Report Years Considered
Figure 5. Global Antibody Drug Conjugate Therapeutics Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Antibody Drug Conjugate Therapeutics Revenue in 2023
Figure 7. Antibody Drug Conjugate Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Mmunomedics Technology Picture
Figure 9. Immunogen Technology Picture
Figure 10. Seattle Genetics Technology Picture
Figure 11. Others Picture
Figure 12. Global Antibody Drug Conjugate Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 13. Global Antibody Drug Conjugate Therapeutics Sales Value Market Share by Type, 2023 & 2030
Figure 14. Product Picture of Lymphoma
Figure 15. Product Picture of Leukemia
Figure 16. Product Picture of Multiple Myeloma
Figure 17. Product Picture of Skin Cancer
Figure 18. Product Picture of Colon Cancer
Figure 19. Product Picture of Glioblastoma
Figure 20. Product Picture of Pancreatic Cancer
Figure 21. Product Picture of Prostate Cancer
Figure 22. Product Picture of Solid Tumor
Figure 23. Product Picture of Breast Cancer
Figure 24. Global Antibody Drug Conjugate Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 25. Global Antibody Drug Conjugate Therapeutics Sales Value Market Share by Application, 2023 & 2030
Figure 26. North America Antibody Drug Conjugate Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 27. North America Antibody Drug Conjugate Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 28. Europe Antibody Drug Conjugate Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 29. Europe Antibody Drug Conjugate Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 30. Asia Pacific Antibody Drug Conjugate Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Antibody Drug Conjugate Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 32. South America Antibody Drug Conjugate Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 33. South America Antibody Drug Conjugate Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 34. Middle East & Africa Antibody Drug Conjugate Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 35. Middle East & Africa Antibody Drug Conjugate Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 36. Key Countries/Regions Antibody Drug Conjugate Therapeutics Sales Value (%), (2019-2030)
Figure 37. United States Antibody Drug Conjugate Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 38. United States Antibody Drug Conjugate Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 39. United States Antibody Drug Conjugate Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 40. Europe Antibody Drug Conjugate Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 41. Europe Antibody Drug Conjugate Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 42. Europe Antibody Drug Conjugate Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 43. China Antibody Drug Conjugate Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 44. China Antibody Drug Conjugate Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 45. China Antibody Drug Conjugate Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 46. Japan Antibody Drug Conjugate Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 47. Japan Antibody Drug Conjugate Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 48. Japan Antibody Drug Conjugate Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 49. South Korea Antibody Drug Conjugate Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 50. South Korea Antibody Drug Conjugate Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 51. South Korea Antibody Drug Conjugate Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 52. Southeast Asia Antibody Drug Conjugate Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 53. Southeast Asia Antibody Drug Conjugate Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 54. Southeast Asia Antibody Drug Conjugate Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 55. India Antibody Drug Conjugate Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 56. India Antibody Drug Conjugate Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 57. India Antibody Drug Conjugate Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 58. Antibody Drug Conjugate Therapeutics Industrial Chain
Figure 59. Antibody Drug Conjugate Therapeutics Manufacturing Cost Structure
Figure 60. Channels of Distribution (Direct Sales, and Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
